adalimumab products — Medica

Initial criteria

• age ≥ 12 years
• tried at least one other therapy (e.g., intralesional/oral corticosteroids, systemic antibiotics, or isotretinoin)
• prescribed by or in consultation with a dermatologist

Reauthorization criteria

• patient established on therapy ≥ 3 months
• beneficial clinical response by objective measure (Hurley staging, Sartorius score, Physician Global Assessment, Hidradenitis Suppurativa Severity Index)
• improvement in symptoms (decreased pain or drainage of lesions, nodules, cysts) vs baseline

Approval duration

initial 3 months, reauth 1 year